Prognostic role of bone sialoprotein in clear cell renal carcinoma

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2679-2688

  Righi, Luisella ^a   Bollito, Enrico ^a   Ceppi, Paolo ^a   Mirabelli, Dario ^b   Tavaglione, Veronica ^a   Chiusa, Luigi ^c   Porpiglia, Francesco ^a   Brunelli, Matteo ^d   Martignoni, Guido ^d   Terrone, Carlo ^e   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Bone sialoprotein; Osteopontin; Prognosis; Renal cell carcinoma

Indexed keywords

BONE SIALOPROTEIN; OSTEOPONTIN; PARAFFIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BONE TUMOR; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS;

BONE SIALOPROTEIN; OSTEOPONTIN; PROGNOSIS; RENAL CELL CARCINOMA;

BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTEGRIN-BINDING SIALOPROTEIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS;

MLCS; MLOWN;

EID: 84881355409     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. McLaughlin JK, Lipworth L and Tarone RE: Epidemiologic aspects of renal cell carcinoma. Semin Oncol 33: 527-533, 2006
2. Murphy WM GD and Perlman EJ: Tumours of the Kidney, Bladder and Related Urinary Structures. Washington: American Registry of Pathology, 2004.
3. Eble JN SG, Epstein JI and Sesterhenn IA: Tumor of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003.
5. Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC and Blute ML: Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 179: 474-477, 2008.
6. Cho KS, Choi YD, Kim SJ Chung BH, Seong do H, Lee DH, Cho JS, Cho IR and Hong SJ: A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 49: 451-458, 2008.
7. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S and Figlin RA: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173: 1496-1501, 2005.
8. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M and Moriyama M: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427, 2008.
9. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer.: Nat Rev Cancer 8: 212-226, 2008.
10. Ogbureke KU and Fisher LW: Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68: 155-66, 2005.
11. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF and Senger DR: Expression and distribution of osteopontin in human tissues. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3: 1169-1180, 1992.
12. McKee MD, Nanci A and Khan SR: Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10: 1913-1929,1995.
13. Valabrega G, Fagioli F, Corso S Madon E, Brach del Prever A, Biasin E, Linari A, Aglietta M and Giordano S: ERB-B2 and bone sialoprotein as markers for metastatic osteosarcoma cells. Br J Cancer 88: 396-400, 2003.
14. Bellahcene A, Menard S, Bufalino R, Moreau L and Castronovo V: Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69: 350-353, 1996.
15. Detry C, Waltregny D, Quatresooz P, Chaplet M, Kedzia W, Castronovo V, Delvenne P and Bellahcene A: Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 73: 9-14, 2003.
16. Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P and Scagliotti GV: Bone sialoprotein is predictive of bone metastases in resectable nonsmall cell lung cancer: A retrospective case control study. J Clin Oncol 24: 4818-4824, 2006.
17. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J and Castronovo V: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90: 1000-1008, 1998.
18. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R and Seibel MJ: Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84: 344-351, 2001.
19. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-73, 2005.
20. Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV and Papotti M: Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 130: 58-64, 2008.
21. Karadag A, Ogbureke KU, Fedarko NS and Fisher LW: Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96: 956-65, 2004.
22. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE and Chung LW: Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65: 2303-2313, 2005.
23. Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: Changing views. J Pathol 214: 283-293, 2008.
24. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623, 1994.
25. Matusan K, Dordevic G, Stipic D, Mozetic V and Lucin K: Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94: 325-331, 2006.
26. Matusan K, Dordevic G, Mozetic V and Lucin K: Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res 11: 108-113, 2005.
27. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA and Jung K: Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133: 643-652, 2007.
28. Fisher LW, Jain A, Tayback M and Fedarko NS: Small integrinbinding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10: 8501-11, 2004.
29. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY and Wang XW: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
30. Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP and Berger MR: Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115: 177-186, 2005.
31. Iiizumi M, Liu W, Pai SK, Furuta E and Watabe K: Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy. Biochim Biophys Acta 1786: 87-104, 2008.
32. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS and Tice DA: Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 5: 3122-3129, 2006.
33. Platt VM and Szoka FC Jr.: Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5: 474-486, 2008.
34. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B and Kuo PC: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26: 741-751, 2005.
35. Lien S and Lowman HB: Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol pp. 131-150, 2008.